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Abstract The aim of the study is to clarify the relation-
ship between adipose tissue dysfunction, metabolic profile
and growth hormone (GH)/insulin-like growth factor
(IGF)-I secretion in healthy adult subjects. We investigated
the metabolic profile in a cohort of 231 consecutive healthy
subjects in relation to GH, IGF-I levels, and visceral adi-
posity index (VAI). Anthropometric measures, lipid pro-
file, and glucose and insulin levels during oral glucose
tolerance test, Homa-IR and ISI Matsuda, IGF-I and GH
peak after GHRH plus Arginine test were analyzed. The
subjects with high VAI showed lower GH peak
(22.8 ± 11.1 vs. 42.2 ± 21.3 lg/L; p = 0.049) and lower
IGF-I (presented as IGF-I under normal range, UNR)
(0.54 ± 0.14 vs. 0.64 ± 0.12; p = 0.005) than group with
normal VAI. ROC curve analysis identified the cut-off,
able to detect subjects with high VAI, i.e., 31.8 lg/L for
GH peak and 0.63 for IGF-1 UNR. The subjects with GH
peak and IGF-I UNR under the cut-off showed significantly
higher levels of VAI, systolic and diastolic blood pressure,
glucose and insulin levels, Homa-IR, and lower ISI Mat-
suda, with a concomitant worse lipid profile (all
p\ 0.001). A strong relationship between GH axis, VAI
and metabolic risk has been demonstrated. A percentage of
apparently healthy subjects show a degree of visceral adi-
pose dysfunction associated with GH and IGF-I levels that
do not meet the criteria of overt GH deficiency (GHD).
Long-term prospective studies could help to clarify and
confirm whether a hypothetical condition of subclinical
GHD could be taken into account as a new clinical entity.
Keywords Growth hormone  Visceral adiposity 
Metabolic risk  GH deficiency
Introduction
Growth hormone deficiency (GHD) in adult life is well
known to be associated with increased fat and reduced lean
mass, altered cardiac structure and function, adverse lipid
profile, glucose intolerance and insulin resistance, and
increased cardiovascular morbidity and mortality [1–7]. On
the other hand, there is robust evidence that obesity results
in a secondary reduction in GH secretion and that sub-
stantial weight loss may restore spontaneous and stimu-
lated GH secretion [8–13]. Body mass index (BMI) is
negatively correlated with GH secretion [10, 11, 14] due
both to reduced GH production and increased GH-clear-
ance [12]. However, how obesity reduces GH secretion has
not been clarified and there is an increasing evidence that
free fatty acids (FFA) play a significant role [15, 16]. In
clinically non-obese healthy adults, relative abdominal
adiposity proved to be a major negative determinant of
stimulated GH secretion [10]. Conversely, the existence of
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changes of the insulin-like growth factor (IGF)-I axis in
obesity is controversial. There are data showing decreased
[14, 17, 18], normal [12, 19] or even elevated [20] IGF-I
levels in adult obese patients.
Adiposity and the GH axis are reportedly tightly inter-
related [21]; data, however, originated mostly in patients
with hypothalamus-pituitary diseases, while in the general
population, data are still limited. The visceral adiposity
index (VAI), a gender-specific mathematical index based
on simple anthropometric [BMI and waist circumference
(WC)] and metabolic [triglycerides (TG) and HDL cho-
lesterol (HDL)] parameters, has been proposed as a sur-
rogate marker of adipose tissue function and distribution,
independently correlated with insulin sensitivity and car-
diometabolic risk in the general population [22]. VAI has
shown to be a good marker of adipose tissue dysfunction in
the general population [22–24] and in populations at met-
abolic risk such as women with PCOS [25], patients with
non-alcoholic fatty liver disease [26], acromegaly [27, 28],
prolactinoma [29] or diabetes mellitus [30, 31].
The current study is based on the hypothesis that fat
distribution and/or function, represented by VAI, correlates
with the GH axis. To clarify this association, we investi-
gated the metabolic profile and the visceral adipose func-
tion in a cohort of consecutive healthy subjects in relation
to GH levels after stimulus test.
Materials and methods
Patients
For the purpose of this study, at the section of Endocrinology
University ‘‘Federico II’’ ofNaples, between January 1st 2009
and December 31st 2011, GH secretion was evaluated after
GHRH plus Arginine (GHRH?Arg) test [32] in 231 subjects,
118 men and 113 women, aged 44.2 ± 20.2 years, recruited
consecutively among the medical and paramedical personnel
of the Department and their relatives, and/or patients’ rela-
tives. The study was part of a large database started in 1997 to
investigate the role of GH on the cardiovascular system,
approved by the Ethical Committee of the ‘‘Federico II’’
University ofNaples in 1997 (no.63/97).An informed consent
has been obtained from each subject after full explanation of
the purpose and nature of all procedures used.
Clinical and biochemical features of subjects enrolled
into the study are shown in Table 1.
The exclusion criteria for entering this study were: (1) diag-
nosis of overtGHdeficiencyorGHexcess (2) personal historyof
pituitary diseases as reported in interviews with individual sub-
jects; (3) previous or current treatments with drugs known to
interfere with glucose or lipid metabolism or to influence blood
pressure; (4) previous treatment with corticosteroids for longer
than 2 weeks; (5) previous or current treatmentwith estrogens or
testosterone for longer than 12 weeks; (6) smoking ofmore than
15cigarettes/day andalcohol abuse (more than3glasses ofwine/
day); (7) presence of previous diagnosis and already known
diabetes mellitus or hypertension; 8) severe obesity. Of initial
296 patients, 65 were excluded since GH levels were assayed
before beginning of use of modern GH assay, in line with
international recommendations [33].
Study design
This is an analytical, retrospective study to analyze the
relationship between the visceral adiposity and GH-IGF-I
secretion in a sample representative of the general popula-
tion. Anthropometric measurements were performed with
Table 1 Clinical and biochemical features of 231 subjects enrolled
into the study
Subjects (%)
Gender
Men 118 (51.1)
Women 113 (48.9)
Mean ± SD
Age (year) 44.2 ± 20.2
BMI (Kg/m2) 28.2 ± 6.5
WC (cm) 89.3 ± 16.8
VAI 1.51 ± 0.81
Basal GH (lg/L) 0.31 ± 0.44
Nadir GH (lg/L) 0.13 ± 0.12
AUCGH (lg/L) 32.5 ± 28.7
GH peak (lg/L) 38.6 ± 21.2
IGF1 (UNR) 0.62 ± 0.13
SDS IGF1 -0.02 ± 0.68
Subjects (%)
Metabolic syndrome 24 (10.3)
High VAI 43 (18.6)
Increased WC 82 (35.5)
Hypertriglyceridemia 42 (18.2)
Low HDL cholesterol 33 (14.3)
Increased Systolic Blood Pressure or
specific treatment
30 (13)
Increased Diastolic Blood Pressure or
specific treatment
14 (6.1)
Impaired fasting glucose (IFG) 24 (10.4)
Impaired glucose tolerance (IGT) 12 (5.2)
IFG ? IGT 26 (11.3)
Diabetes mellitus (DM) 22 (9.5)
BMI body mass index, WC waist circumference, VAI visceral adi-
posity index, AUC area under the curve, UNR under the average of the
normal range for age, and SDS standard deviation score
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the subjectswearing only underwearwithout shoes. Standing
height was measured to the nearest cm using a wall-mounted
stadiometer. Bodyweightwas determined to the nearest 50 g
using a calibrated balance beam scale. BMIwas calculated as
weight (kg) divided by height squared (m2). Waist circum-
ference (WC) was measured at the midpoint between the
lower rib and the iliac crest. Systolic (SBP) and diastolic
(DBP) blood pressure were measured in all patients. Patients
were analyzed according to each criterion of the metabolic
syndrome (MS) [34] and each category of glucose tolerance
(GT) [35]. After an overnight fast, lipid profile (total, HDL
and LDL cholesterol, and triglycerides) glucose and insulin
levels, and IGF-I were measured. IGF-I levels were reported
as standard deviation score (SDS) age- and gender-adjusted.
In addition, we calculated the ratio of the observed serum
IGF-I levels to the average of the normal range for age. The
data were presented as IGF-I under normal range (IGF-I
UNR) and we considered equal to 1, the perfectly average
IGF-I value and\1 the IGF-I levels below the average. The
GHRH ? Arg test was performed as previously reported
[36].Arginine (arginine hydrochloride, Salf, Bergamo, Italy)
was given at the dose of 0.5 g/Kg, up to a maximal dose of
30 g slowly infused from time 0 to 30 min, while GHRH
(Geref, Serono, Rome, Italy and GHRH Ferring, Milan,
Italy) was given at the dose of 1 lg/Kg as i.v. bolus at time 0.
Blood sampleswere taken every 30 min from0up to 90 min.
The highest GH levels measured from time 30 to 90 min
during the test were taken for analysis as peak GH. The area
under the curve (AUC) of GH (AUCGH) was calculated.
The oral glucose tolerance test (oGTT) was performed by
measuring plasma blood glucose and insulin every 30 min for
2 h after 75 g oral glucose load. TheAUCof glucose (AUCGLU)
and insulin (AUCINS) during 2 h-OGTT were calculated. Basal
insulin resistance (IR) was assessed using homeostasis model
assessment of the insulin resistance (Homa-IR) index [37],while
the stimulated insulin sensitivity was measured using the insulin
sensitivity index (ISI), a composite index derived from the
OGTT and validated by Matsuda et al. [38].
As the surrogate of visceral fat function in all patients,
we calculated VAI as described [22], using the following
formulas differentiated according to sex, where TG is
fasting triglycerides levels expressed in mmol/L and HDL
is HDL cholesterol levels expressed in mmol/L:
Males : VAI
¼ WC=39:68 þ 1:88  BMIð Þ½   TG=1:03ð Þ
 1:31=HDLð Þ;
Females : VAI
¼ WC=36:58 þ 1:89  BMIð Þ½ 
 TG=0:81ð Þ  1:52=HDLð Þ:
According to specific age-stratified cut-off points of
VAI identifying patients with presumed visceral adipose
dysfunction and cardiometabolic risk, we grouped the
entire cohort of patients into those with normal and high
VAI. The appropriate cut-off points of VAI used were
previously calculated in a general population as follows:
2.52 for subjects under 30 years, 2.23 for those aged
between 30 and 42 years, 1.92 between 42 and 52 years,
1.93 between 52 and 66 years, and 2.00 for subjects over
66 years [23].
Hormone and biochemical assays
Glycemia and lipid levels were measured in centralized
accredited laboratories with standard methods. Serum
insulin was measured by ELISA (DRG Instruments GmbH,
Germany). The sensitivity of the method was 1 IU/mL.
The normal insulin range (IU/mL) was 5–19. Serum GH
was measured by CLIA using Liaison hGH kit of Diasorin.
The hGH sensitivity is 0.052 lg/L, thus undetectable GH
levels were arbitrarily considered 0.05 lg/L. The intra-
assay CVs were 4.4, 1.6, and 2.0 % for the low, medium,
and high points of the standard curve, respectively. The
inter-assay CVs were 6.0, 7.7, and 6.8 % for the low,
medium, and high points of the standard curve. The hGH
values were evaluated against the World Health Organi-
zation Second International Standard reference reagent
98/574. Serum IGF-I was measured by CLIA after auto-
matized extraction using Liaison IGF-I kit of DiaSorin. The
IGF-I sensitivity is\3 lg/L. The intra-assay CVs were 4.3,
3.0, and 3.3 % for the low, medium, and high points of the
standard curve, respectively. The inter-assay CVs were 4.4,
3.3, and 3.6 % for the low, medium, and high points of the
standard curve. The IGF-I values were evaluated against
1st WHO International Standard for Insulin-like Growth
Factor-I NIBSC 02/254.
Statistical methods
The Statistical Packages for Social Sciences SPSS version
17 and MedCalc version 11.3 were used for data analysis.
Baseline characteristics were presented as mean ± stan-
dard deviation (SD) for continuous variables; rates and
proportions were calculated for categorical data. Nor-
mality of distribution for quantitative data was assessed
by Kolmogorov–Smirnov test. Differences between
groups were detected by unpaired Student’s t test for
continuous variables and by v2-test, and Fisher’s exact
test (when appropriate) for categorical variables. Differ-
ences in hormonal parameters (GH-IGF-1 axis) were
calculated after being adjusted for age and for all
494 Endocrine (2015) 49:492–502
123
metabolic parameters, excluding the collinear variables
with VAI, resulted significantly different between the two
groups, using a logistic regression model. Receiver
operating characteristic (ROC) analysis was used to assess
the ability of GH peak, IGF-I UNR, Homa-IR, ISI Mat-
suda, total and LDL cholesterol, AUCGLU, and AUCINS to
indicate increased VAI score. ROC curves indicate the
probability of a true-positive result as a function of the
probability of a false positive result for all possible
threshold values of above selected parameters. ROC curve
analysis was performed using the MedCalc software
(version 11.3.0 for Windows), which uses calculation of
the area under the curve (C-statistic) and 95 % confidence
intervals by the technique of Hanley and McNeil. Statis-
tical significance of the difference between C-statistic of
GH peak and IGF-1 UNR and the other parameters
(Homa-IR, ISI Matsuda, total cholesterol, AUCGLU, and
AUCINS) separately was calculated by the method of
Hanley and McNeil. A p value of\0.05 was considered
statistically significant.
Table 2 Subjects features in relation to visceral adiposity index (VAI)
Subjects with normal VAI No 188
(81.4 %)
Subjects with high VAI No 43
(18.6 %)
Univariate
analysis
Multivariate
analysis*
Mean ± SD Mean ± SD p p OR (IC 95 %)
Age (years) 41.6 ± 19.8 55.8 ± 18.2 \0.001
BMI (Kg/m2) 27.6 ± 6.7 30.8 ± 5.1 0.003
WC (cm) 86.4 ± 15.9 102.2 ± 14.5 \0.001
Systolic blood pressure
(mmHg)
124.6 ± 15.5 136.5 ± 10.6 0.009
Diastolic blood pressure
(mmHg)
79 ± 7.3 83 ± 4.3 0.054
Total cholesterol levels
(mmol/L)
4.95 ± 0.78 6.10 ± 0.74 \0.001
HDL cholesterol levels
(mmol/L)
1.48 ± 0.17 1.23 ± 0.11 \0.001
LDL cholesterol levels
(mmol/L)
2.91 ± 0.79 4.06 ± 0.74 \0.001
Triglycerides levels (mmol/
L)
1.21 ± 0.32 1.78 ± 0.25 \0.001
Fasting glucose levels
(mmol/L)
5.07 ± 0.20 6.06 ± 0.74 \0.001
Fasting insulin levels
(mmol/L)
9.42 ± 5.64 13.16 ± 6.06 \0.001
AUCglucose (mmol/L) 967 ± 189 1108 ± 190 \0.001
AUCinsulin (mmol/L) 7597 ± 5209 9282 ± 6362 0.068
Homa-IR 2.2 ± 1.5 3.5 ± 1.6 \0.001
ISI Matsuda 5.9 ± 3.8 3.4 ± 1.8 \0.001
Basal GH (lg/L) 0.35 ± 0.47 0.13 ± 0.21 0.005 0.076
0.28 (0.07–1.14)
AUCGH (lg/L) 35.2 ± 29.6 20.6 ± 21.2 0.003 0.896
0.99 (0.98–1.05)
Nadir GH (lg/L) 0.14 ± 0.13 0.08 ± 0.07 0.003 0.621
0.29 (0–36.55)
GH peak (lg/L) 42.2 ± 21.3 22.8 ± 11.1 \0.001 0.049
0.96 (0.93–1)
IGF1 (UNR) 0.64 ± 0.12 0.54 ± 0.14 \0.001 0.005
0.01 (0–0.29)
SDS IGF1 0.05 ± 0.67 -0.03 ± 0.65 \0.001 0.017
0.54 (0.32–0.89)
* Values adjusted for age and for all metabolic parameters, excluding the collinear variables with VAI, resulted significantly different between
the two groups (p\ 0.05), using a logistic regression model
VAI visceral adiposity index, BMI body mass index, WC waist circumference, AUC area under the curve, UNR under the average of the normal
range for age, and SDS standard deviation score
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Results
The clinical and biochemical features of subjects are shown
in Table 1. In the entire cohort of subjects, the mean GH
peak after GHRH?Arg test was 38.6 ± 21.2 lg/L. None
of the subjects had GH peak after GHRH?ARG below
9.1 lg/L, the currently accepted cut-off to diagnose adult
GH deficiency [39], nor had GH peak between 9.1 and
16.5 lg/L, representing the 1st and the 3rd percentile of the
general population according with Aimaretti et al. [32].
The mean IGF-I SDS was -0.02 ± 0.68, with a mean IGF-
I UNR 0.62 ± 0.13.
Using the ‘‘National Cholesterol Education Program
(NCEP-Adult Treatment Panel III, ATP III)’’ criteria [34],
in the whole cohort of subjects, the overt complete MS was
found in 24 subjects (10.3 %). Specifically, 30 (13 %)
subjects had systolic hypertension, 14 had (6.1 %) diastolic
hypertension, 42 (18.2 %) had hypertriglyceridemia, 82
(35.5 %) had increased WC, and 33 (14.3 %) had low HDL
cholesterol levels (Table 1).
Twenty-four out of 231 subjects (25 %) were classified
as having impaired fasting glucose (IFG), 12 (5.2 %)
impaired glucose tolerance (IGT), 26 (11.3 %) IFG ? IGT,
and 22 (9.5 %) showed after OGTT a previously unknown
overt diabetes mellitus (DM), according to the medical
guidelines of the American Association of Clinical Endo-
crinologists [35].
In the entire cohort of subjects, the mean VAI was
1.51 ± 0.81. One hundred and eighty-eight subjects (81.4 %)
were classified as having normal VAI, while 43 (18.6 %) had
high VAI. The subjects with high VAI were older
(55.8 ± 18.2 vs. 41.6 ± 19.8 years; p\ 0.001) and with
greater BMI (30.8 ± 5.1 vs. 27.6 ± 6.7 kg/m2; p = 0.003)
than thosewith lowerVAI. In addition, subjectswithhighVAI
showed a significant worse lipid and glucose profile than
subjects with lowerVAI, with a concomitant higher Homa-IR
(3.5 ± 1.6 vs. 2.2 ± 1.5; p\ 0.001) and lower ISI Matsuda
(3.4 ± 1.8 vs. 5.9 ± 3.8;p\ 0.001) (Table 2).No difference
was found in basal GH (0.13 ± 0.21 vs. 0.35 ± 0.47 lg/L;
p = 0.076), AUCGH (20.6 ± 21.2 vs. 35.2 ± 29.6;
p = 0.896), and nadir GH during OGTT (0.08 ± 0.07 vs.
0.14 ± 0.13 lg/L; p = 0.621) when hormonal values were
adjusted for age and all significantmetabolic variables using a
logistic regression model. Conversely, group of subjects with
high VAI showed lower GH peak after GHRH ? Arg
(22.8 ± 11.1 vs. 42.2 ± 21.3 lg/L; p = 0.049), IGF-I UNR
(0.54 ± 0.14 vs. 0.64 ± 0.12; p = 0.005), and IGF-I SDS
(-0.03 ± 0.65 vs. 0.05 ± 0.67; p = 0.017) than group with
normal VAI (Table 2).
In order to identify the optimal cut-off point, able to
detect subjects with high VAI, ROC curve analysis was
performed for GH peak, IGF-I UNR, Homa-IR, ISI Mat-
suda, Total Cholesterol, LDL Cholesterol, AUCglucose, and
AUCinsulin (Table 3). The C-statistics were then compared
to verify the predictive values of the above-mentioned
parameters. No significant differences were found between
the C-Statistics of GH peak, IGF-I UNR and Homa-IR, ISI
Matsuda, total cholesterol, AUCglucose, and AUCinsulin
(Table 4).
GH peak and IGF-I UNR threshold levels, calculated by
maximizing the combined specificity and sensitivity in the
ROC curves, were 31.8 lg/L (sensitivity: 83.7 %; speci-
ficity: 63.8 %) and 0.63 (sensitivity: 79.1 %; specificity:
56.9 %), respectively (Table 3).
Considering the cut-off of 31.8 lg/L for GH peak and of
0.63 for IGF-I UNR, we grouped the subjects into those
with at least a value higher than the above-mentioned cut-
off (Group A, No 168; 72.7 %) and those with low values
of both GH peak and IGF-I UNR (Group B, No 63;
27.3 %). The subjects with values under cut-off were older
(51.4 ± 22.7 vs. 41.6 ± 18.6 years; p = 0.001) and with a
higher prevalence of men than women (p = 0.044). In
addition, the subjects with GH peak\ 31.8 lg/L and IGF-I
UNR\ 0.63 showed significantly higher levels of VAI
(2.12 ± 0.85 vs. 1.28 ± 0.67; p\ 0.001), systolic
(144.2 ± 11.5 vs. 122.6 ± 13.8 mm/Hg; p\ 0.001) and
diastolic blood pressure (86 ± 4.5 vs. 78.2 ± 6.9 mm/Hg;
p\ 0.001), Homa-IR (4 ± 1.9 vs. 1.9 ± 1.1; p\ 0.001),
fasting glucose (2.75 ± 0.34 vs. 2.33 ± 0.35 mmol/L;
p\ 0.001), AUCglucose (1103 ± 209 vs. 952 ± 176 mmol/
L; p\ 0.001), fasting insulin (15.12 ± 6.95 vs.
8.24 ± 4.11 mmol/L; p\ 0.001), AUCinsulin (10985 ±
6814 vs. 6757 ± 4361 mmol/L; p\ 0.001), and lower ISI
Matsuda (3 ± 1.6 vs. 6.4 ± 3.8; p\ 0.001), with a con-
comitant worse lipid profile (Figs. 1, 2).
Discussion
We investigated the metabolic profile and the visceral
adipose function, indirectly expressed by VAI, in a group
of subjects without overt GH axis dysfunction in relation to
GH and IGF-I levels, and their mutual relationship. Our
data show a strong correlation between visceral adiposity
and GH axis, highlighting how GH values quite higher than
those recognized as diagnostics for overt GHD could be
associated with a condition of visceral adiposity dysfunc-
tion and cardiometabolic risk.
Currently, the peak GH response less than 3.0 lg/L to
an insulin tolerance test (ITT) is considered the gold
standard for the biochemical diagnosis of severe adult
GHD [40, 41], while Aimaretti et al. showed that the
combined administration of arginine, which presumably
reduces hypothalamic somatostatin secretion, and GHRH is
safe and provides a strong stimulus to GH secretion and
thus could be used as an alternative test of pituitary GHD,
496 Endocrine (2015) 49:492–502
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with a cut-off of 9.1 lg/L [32]. In addition, it would be
reasonable to use different GH cut-off points according to
BMI for the stimulus test. In fact, peak of GH has to be
normalized for age and BMI as young, and lean people
produce physiologically more GH under stimulation [21,
36, 42, 43]. Corneli et al. showed that the appropriate cut-
off points for diagnosing GHD were 11.5 lg/L for those
with a BMI less than 25 kg/m2, 8.0 lg/L for a BMI of
25–30 kg/m2, and 4.2 lg/L for those with a BMI greater
than 30 kg/m2 [44]. As stimulation test, the
GHRH ? ARG test was chosen in this study because of
previous studies showing reliable comparison with ITT
[32], reliable cut-off for the GHD diagnosis, as correlated
with lipid, bone and cardiac status [45–47], and high
reproducibility [48].
Conversely, it is a matter of fact that the analysis of IGF-
I levels is not sufficient to diagnose GHD, though increased
IGF-I levels are essential to diagnose GH excess. Reduced
IGF-I levels are not required to diagnose GHD as many
patients with clear-cut GHD might have normal IGF-I
levels. The usefulness of an IGF-I estimation in the diag-
nosis of adult GHD is a matter of contention. Hoffman
et al. found [49] that 70 % of IGF-I values in adult-onset
GHD patients were within the range of normal subjects
[49], while a low IGF-I level, in the absence of catabolic
conditions such as poorly controlled diabetes, liver disease,
and oral estrogen therapy, is strong evidence for significant
GHD and may be useful in identifying patients who may
benefit from treatment, and therefore require GH stimula-
tion testing [41].
Two previous studies have demonstrated that GH peak
after GHRH ? ARG [36] and GH nadir during OGTT [43]
depend on age, BMI, and waist circumference so that
appropriate diagnostic cut-off should consider these vari-
ables. The role of BMI has been clearly demonstrated to
modify GH peak after GHRH ? ARG in large series of
hypopituitary patients by Corneli et al. [44], but BMI only
partially reflect visceral adiposity. In fact, in a study
including both WC and BMI as predictors of response [36],
a stronger effect of the former on the latter has been
demonstrated. Similarly WC, more than BMI, suppressed
Table 3 Area under ROC curves of selected metabolic parameters and related optimal cut-off point to detect subjects with high VAI
Cut-off point Sens. (%) Spec. (%) Area under ROC curve SE 95 % CI p
GH peak \31.8 83.7 63.8 0.767 0.03 0.70–0.82 \0.001
IGF-1 UNR \0.63 79.07 56.91 0.709 0.04 0.64–0.76 \0.001
Homa-IR [2.7 72.09 74.47 0.758 0.04 0.69–0.81 \0.001
ISI Matsuda \4.1 79.07 61.17 0.715 0.03 0.65–0.77 \0.001
Total cholesterol [5.47 79.07 78.72 0.852 0.03 0.79–0.89 \0.001
LDL cholesterol [ 3.53 76.74 79.79 0.847 0.03 0.79–0.89 \0.001
AUCglucose [967.3 81.40 65.96 0.729 0.04 0.66–0.78 \0.001
AUCinsulin [6570 65.12 64.89 0.609 0.04 0.54–0.67 0.027
Sens sensitivity, Spec specificity, SE standard error, VAI visceral adiposity index, UNR under the average of the normal range for age, and AUC
area under the curve
Table 4 Pairwise comparison between C-statistic of GH peak–IGF-1
UNR and Homa-IR, ISI Matsuda, total cholesterol, AUCglucose, and
AUCinsulin
Differences
between
C-statistics
SE 95 % CI p
GH peak versus
Homa-IR
0.008 0.03 -0.06 to
0.008
0.807
GH peak versus ISI
Matsuda
0.052 0.03 -0.01 to
0.12
0.146
GH peak versus
total cholesterol
0.084 0.04 0–0.17 0.056
GH peak versus
AUCglucose
0.038 0.04 -
0.04–0.12
0.191
GH peak versus
AUCinsulin
0.158 0.05 0.05–0.26 0.063
IGF-1 UNR versus
Homa-IR
0.049 0.05 -0.05 to
0.14
0.333
IGF-1 UNR versus
ISI Matsuda
0.005 0.05 -0.09 to
0.10
0.912
IGF-1 UNR versus
total cholesterol
0.142 0.05 0.04–0.24 0.064
IGF-1 UNR versus
AUCglucose
0.019 0.05 -0.08 to
0.12
0.714
IGF-1 UNR versus
AUCinsulin
0.100 0.06 -0.01 to
0.22
0.101
GH peak versus
IGF-1 UNR
0.057 0.04 -0.02 to
0.14
0.185
AUC area under the curve, UNR under the average of the normal
range for age
C-statistic were 0.767 (95 % CI 0.70–0.82) for GH peak, 0.709 (95 %
CI 0.64–0.76) for IGF-1 UNR, 0.758 (95 % CI 0.69–0.81) for Homa-
IR, 0.715 (95 % CI 0.65–0.77) for ISI Matsuda, 0.852 (95 % CI
0.79–0.89) for total cholesterol, 0.847 (95 % CI 0.79–0.89) for LDL
Cholesterol, 0.729 (95 % CI 0.66–0.78) for AUCglucose, and 0.609
(95 % CI 0.54–0.67) for AUCinsulin
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GH nadir after OGTT [43]. Despite this evidence, cut-off
peak GH and nadir GH after stimuli are still considered
worldwide without an appropriate cut-off for WC.
Ideally, the possibility to use one single value repre-
senting at the same time BMI, WC, and lipid profile could
be very useful, and in this light VAI might help in deter-
mining the best stratification of GH secretion in relation to
cardiometabolic risk. In this study, we found that GH
values, after GHRH-Arg test lower than 31.8 lg/L with
IGF-I UNR lower than 0.6, are associated with a cardio-
metabolic risk status, represented by high VAI.
It is well known that overt GHD in adults has been
associated with an adverse metabolic profile and abnor-
malities in body composition that may have an impact on
cardiovascular risk. In fact, a clustering of cardiovascular
clinical risk factors has been reported in GHD patients,
including truncal adiposity and increased visceral fat,
changes in body composition and insulin resistance,
negative changes in lipid profiles and abnormal hemo-
static factors, and an increased cardiovascular mortality
[50–52].
In our cohort of subjects, we found a higher prevalence
of subjects with high VAI than patients with overt MS.
These findings are in line with previous data [22] and a
possible explanation might lie in the fact that the early
stages of metabolic alterations are not highlighted by the
classic criteria of MS, whereas VAI seems to be able to
show early signs of metabolic risk in patients without overt
MS, since the variables are treated as continuous variables
and not as dichotomous.
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Fig. 1 Differences in visceral adiposity index (VAI), AUCglucose,
Homa-IR, and ISI Matsuda between subjects with GH peak lower
than cut-off of 31.8 lg/L and IGF-1 UNR lower than cut-off of 0.63
(Group A), and those with at least a value higher than the above-
mentioned cut-off (Group B)
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As expected, patients with high VAI were older, with
higher BMI, and with worse lipid and glucose profile, and
these data seem to be in agreement with those of Fieffe
et al., which showed that age and BMI are significant risk
factors of metabolic alterations and type 2 diabetes [53]. In
addition, this group of subjects also showed lower peak of
GH after GHRH–Arg test and lower IGF-I levels. In this
view, the subjects with lower GH and IGF-I have more
severe visceral adipose dysfunction. We found that the GH
and IGF-I cut-off derived from ROC analysis resulted in
higher values than those recognized as diagnostic for adult
GHD. The cut-off found is associated with a better and
satisfactory area under the ROC curve to detect with a good
accuracy the subjects with high VAI. Then the parameters
GH peak and IGF-I resulted as having a comparable good
sensitivity and specificity to detect a condition of cardio-
metabolic risk to that of other metabolic parameters asso-
ciated with this risk, as Homa-IR, ISI Matsuda, lipid
profile, and AUC of glucose and insulin during OGTT.
These data have been confirmed when we grouped the
subjects in relation to GH and IGF-I levels below or
beyond the above-mentioned cut-off. In fact, the 63 sub-
jects who had both GH and IGF-I levels below the estab-
lished cut-off, predominantly of male gender and older,
showed higher VAI and a worse cardiometabolic profile, in
terms of higher systolic and diastolic blood pressure, higher
glucose and insulin levels, lower degree of insulin sensi-
tivity, and worse lipid profile.
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of 31.8 lg/L and IGF-1 UNR lower than cut-off of 0.63 (Group A),
and those with at least a value higher than the above-mentioned cut-
off (Group B)
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In our hypothesis, the existence of continuum of GH
peak responses to stimulation test between the normal
peak and those recognized as diagnostic for severe GHD
could clarify these findings. If the overt adult GHD is
associated with a well-known clinical syndrome charac-
terized by altered body composition, reduced bone min-
eralization, unfavorable lipid profile, reduced cardiac
performance, early atherosclerosis, and impaired quality
of life [1, 7, 54], we demonstrated that some clinical
feature of this syndrome may also be present with GH
levels much higher than those used for the diagnosis of
adult GHD, outlining a condition of subclinical GHD. In
previous studies, performed both in children and adults,
the condition of partial GHD, which are in between the
severe GHD and the normal GH secretion, is associated
with abnormal growth velocity, body composition, insu-
lin sensitivity, and cardiometabolic risk [55–57]. Even if
partial or subclinical GHD in adults is not recognized as
a clinical entity [39], the current study supports initial
findings that show metabolic alterations even in subjects
with GH values that do not meet the diagnostic criteria
for overt GHD. We found a well highest percentage of
high VAI than MS in our population, supporting the
finding that high VAI identifies an early condition of
cardiometabolic risk, even without an overt MS. These
data are of greater value if we consider that the study
population is resident in southern Italy, where the prev-
alence of MS is higher than in other regions, but this
could also be a limitation of the current study, given that
the prevalence of IFG, IGT, DM, and overweight in our
population was found to be slightly greater.
In conclusion, a strong relationship among GH axis,
VAI and cardiometabolic risk has been demonstrated in
this cohort of subjects. A percentage of 27.3 % of appar-
ently healthy subjects show a degree of visceral adipose
dysfunction associated with GH and IGF-I levels without
overt GHD. Long-term prospective studies could help to
clarify and confirm whether a hypothetical condition of
subclinical GHD in adults could be taken into account as a
new clinical entity.
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